Roche To Make Further In-Roads With Evrysdi In Newborn And Older SMA Patients
50% Of Older US Patients Untreated
Executive Summary
Roche’s Evrysdi is set to expand its license into pre-symptomatic children this year but the company is also focused on how to get greater numbers of older patients to seek treatment.
You may also be interested in...
It Takes A Village: Roche’s India Rare Disease Approach, Crowdfunding Support
Roche Pharma India CEO and managing director, V Simpson Emmanuel, outlines the company's multi-forked approach, including collaborating with a crowdfunding platform, to move the access and treatment needle for Evrysdi in India. The Swiss firm, along with industry associations, also suggests the need for a formal accelerated regulatory pathway in India for rare diseases.
Bayer Shuffles Atara’s CAR-Ts Out Of Its Cell Therapy Deck
Bayer is handing back rights to two early-stage off-the-shelf CAR-Ts to Atara, but the split could still be good news for the biotech company.
Bavarian Nordic Rises As It Meets Demand For Monkeypox Vaccine
The Danish company has the world’s only licensed monkeypox vaccine and is now fielding enquiries from concerned governments from around the world.